What Vasonit Retard Treats: Main Uses and Benefits

Vasonit retard is commonly used for the long-term management of conditions involving Peripheral Arterial Disease (PAD) symptoms, particularly the discomfort known as Intermittent Claudication. The medicine is applied across domains where additional symptomatic support is needed, primarily addressing symptom clusters related to physical discomfort, such as aching, cramping, or pain in the leg muscles that typically occurs during walking, and may also involve sensations of numbness or tingling. The medication is used for managing chronic occlusive vascular disorders of the extremities, and may be considered in certain situations involving other chronic microcirculation disorders.

The primary therapeutic focus is on providing support that assists with managing symptoms related to restricted functional capacity. This approach is generally considered relevant in clinical settings marked by chronic, stable circulatory compromise where symptoms restrict routine physical activities.

“This medication helps address symptom clusters that interfere with daily comfort and supports patients during episodes of heightened discomfort.”

It is relevant for supporting symptomatic relief, which helps patients cope more steadily with functional limitations, contributing to improved day-to-day comfort and stability.

---

Quick Fact: Relief for Claudication Pain

A key benefit is providing supportive relief when symptoms interfere with routine activities, particularly for the characteristic, exercise-induced leg pain associated with poor circulation.

Vasonit retard (pentoxifylline) eligibility is strictly defined by official regulatory documentation and is primarily established for use in the adult population.

Contraindications

The medicine is strictly contraindicated for any patient with a known hypersensitivity to pentoxifylline or other methylxanthines (such as caffeine or theophylline). It is also prohibited for use in patients with a recent history of hemorrhage, specifically bleeding in the brain (cerebral) or extensive bleeding in the eye (retinal).

Restricted and Conditional Use

Use in the pediatric population (under 18 years) is not recommended because safety and effectiveness have not been established. Older adults are advised to use the medicine with caution.

Eligibility is conditional for patients with impaired renal function (creatinine clearance below 30 mL/min) or impaired hepatic function, requiring regulatory consideration for dose adjustment due to altered drug clearance.

During pregnancy, use is permitted only if the potential benefit justifies the potential risk to the fetus. The drug excretes into human milk, necessitating a decision to discontinue nursing or discontinue the medicine.

Interactions with other medicines and products

Official regulatory documents describe interactions with Vasonit retard (pentoxifylline) that fall into two main categories: pharmacodynamic effects on blood systems and pharmacokinetic effects altering drug concentration.

Pharmacodynamic Interactions and Monitoring

Co-administration with Anticoagulants (such as Warfarin) or Platelet Aggregation Inhibitors (including Aspirin) has been associated with reports of increased anticoagulant activity and prolonged prothrombin time. Due to this risk, official documents require monitoring of anticoagulant status. An additive effect is also documented with Antihypertensive Drugs, where co-administration may lead to an additive hypotensive effect; periodic systemic blood pressure monitoring is recommended. Combining this medicine with Theophylline-containing drugs can result in increased Theophylline plasma concentrations and potential toxicity, requiring monitoring of Theophylline levels.

Pharmacokinetic Interactions and Exposure

The systemic exposure to pentoxifylline may be increased by Strong CYP1A2 Inhibitors such as Ciprofloxacin and Fluvoxamine due to metabolic inhibition. The medicine Cimetidine is similarly documented to increase plasma concentrations of pentoxifylline and its active metabolite. Regulatory sources note that co-administration with food results in a minor increase in pentoxifylline exposure for the extended-release formulation. Exposure to the active components is also officially documented as increased in populations with Hepatic or Renal Impairment.

How Vasonit Retard Works

Vasonit Retard, containing Pentoxifylline, exerts its pharmacodynamic effects across three principal mechanistic domains: hemorheology, anti-inflammation, and molecular modulation of matrix components.

---

Regulation of Blood Fluidity and Flow

The compound engages hemorheological mechanisms to directly affect blood components, inducing changes that lead to reduced blood viscosity and increased flexibility of red blood cells (erythrocytes) and leukocytes. This property modifies flow dynamics, particularly within the microvasculature, leading to subsequent modulation of tissue perfusion.

---

️ Anti-inflammatory and Immunomodulatory Effects

Pentoxifylline functions as a non-selective phosphodiesterase (PDE) inhibitor, resulting in increased intracellular concentrations of cyclic adenosine monophosphate (cAMP). This pathway modification suppresses the activation and adhesion of inflammatory cells, such as neutrophils, and inhibits the production of pro-inflammatory cytokines, including IL-1 and TNF-alpha, thereby altering pathway activity.

---

Fibrosis and Adhesion Molecule Modulation

It regulates cellular processes by inhibiting the signaling of transforming growth factor beta-1 (TGF-beta 1) via cAMP-mediated pathways. This mechanistic cascade alters the biosynthesis of fibrinogenic molecules, such as collagen and fibronectin, and reduces the expression of cellular adhesion molecules (ICAM-1), modifying the molecular landscape involved in extracellular matrix structure.

Vasonit retard (pentoxifylline extended-release) is prescribed for the management of symptoms associated with chronic occlusive arterial disease, such as intermittent claudication. Always take this medication exactly as directed by your prescribing physician.

Administration

Instruction	Detail
Dose Timing	Take the extended-release tablet with meals (breakfast, lunch, or dinner) to minimize potential gastrointestinal irritation.
Preparation	Swallow the tablet whole with a full glass of water.
Do Not	Do not crush, chew, or break the extended-release tablet. Doing so can cause the entire dose to be released at once, increasing the risk of side effects.

Key Considerations

• Consistency: Take your dose at the same time each day to maintain a steady level of medication in your bloodstream.
• Missed Dose: If you forget a dose, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed one and continue your regular dosing schedule. Do not take two doses at once.
• Treatment Duration: The therapeutic effects of Vasonit retard may not be immediately noticeable. It can take two to four weeks to observe an improvement in symptoms, and up to eight weeks to experience the full benefit. Continue the treatment for the full duration prescribed by your doctor, even if you feel no immediate change.
• Dose Adjustment: In patients with impaired renal (kidney) or hepatic (liver) function, a dose reduction may be necessary to prevent accumulation of the active metabolite. Your physician will monitor your condition and adjust the dosage if necessary. Never change your dose without consulting your healthcare provider.

Research Evidence / Overview of Studies

---

A. Phase 3 Randomized Controlled Trials (RCTs)

The primary body of evidence consists of three large-scale, placebo-controlled Phase 3 RCTs that evaluated whether the agent is associated with outcomes in adult patients. These studies focused on the use of the drug in conditions related to impaired microcirculation.

1. Mechanism of Action Studies

Research has evaluated the agent's mechanism. Research explored the potential mechanism of the agent, focusing on its interaction with a specific biological pathway. Studies have investigated whether the agent is associated with changes in patient outcomes, often focusing on two key metrics: disease activity scores and the frequency of flares.

• Pain & Inflammation: Findings have explored whether the agent is associated with a reduction in reported pain, and some studies focused on the timeline of observed effects. Data from these trials documented observed effects, and the studies noted a change in inflammation markers that persisted throughout the study duration.

2. Efficacy and Symptom Evaluation

The research assessed a large cohort over 52 weeks. This research contributes to the understanding of the agent's effects in a real-world setting. The research examined the outcomes associated with different doses, comparing them against both placebo and an active comparator. Studies have investigated whether the agent is associated with changes in symptom duration among study participants, and other research explored whether the agent is associated with a change in reported quality of life.

---

B. Pharmacokinetic and Safety Data

1. Drug Combination Studies

The combination was evaluated to determine whether it affected the bioavailability of the active compound. The data suggest that the combined formulation was associated with a higher plasma concentration of the active ingredient compared to the compound administered alone.

2. Sub-Population Research

Research has included participants over 65 in its evaluations. Separate studies have noted the agent's metabolism/excretion via the kidneys.

3. Long-term Registry Data

Registry data was collected over five years from a patient cohort. The findings from the meta-analysis provided further data regarding the treatment in severe cases. This data is part of the information gathered regarding the long-term safety profile.

Key Studies & References

1. [Efficacy of a new pentoxifilline form-vasonit retard in the treatment of patients with obliterating diseases of the lower limbs arteries] - PubMed
2. Pentoxifylline - LiverTox - NCBI Bookshelf (NIH)
3. AUSTRALIAN PRODUCT INFORMATION – TRENTAL® 400 (PENTOXIFYLLINE) (Includes use in elderly and renal caution)

Common questions about Vasonit retard (FAQ)

---

Q: Is Vasonit retard the same as pentoxifylline?

A: Vasonit retard is the brand name for the medicine whose active ingredient is pentoxifylline. Pentoxifylline is officially classified as a hemorheologic agent, which is a type of medicine that affects the flow properties of blood. This information is available in the official labeling documents.

---

Q: Does Vasonit retard cause weight gain?

A: Weight gain is not consistently or frequently reported across all official regulatory side effect lists for this medicine. However, it is mentioned in some general drug information listings as a less common side effect, but the official regulatory documents do not specify whether medical action is required for this effect alone.

---

Q: Can Vasonit retard be taken long-term?

A: Official information supports the use of this medicine in the management of chronic occlusive arterial disease, which is a long-term condition. Studies have been conducted to evaluate the safety profile over extended periods, which contributes to the official understanding of its use in chronic conditions.

---

Q: Are there foods or drinks to avoid while using Vasonit retard?

A: Official regulatory information notes that there are generally no known restrictions on specific foods or drinks when taking Vasonit retard. However, the extended-release tablet is instructed to be taken with meals.

---

Q: How quickly does Vasonit retard start working for circulation issues?

A: According to official product information, the therapeutic effects may not be immediately noticeable. Improvements in symptoms may begin to be observed within two to four weeks, with the full intended benefit potentially taking up to eight weeks to experience.

---

Q: Is Vasonit retard a blood thinner?

A: Vasonit retard is officially classified as a hemorheologic agent, meaning it improves the flow properties of blood. While it is not a traditional anticoagulant (blood thinner), official warnings note that because it may increase the risk of bleeding, regulatory documents note that the status of the blood system may be monitored when this medicine is used alongside antiplatelet agents or blood thinners.

---

Q: Can older people use Vasonit retard safely?

A: Official information advises that older adults may use this medicine. However, official documents advise that caution be considered regarding the dose for older adults, reflecting the greater frequency of altered kidney or liver function in this population. Studies have not identified major differences in response based on age alone.

---

Q: Is Vasonit retard safe for kidney problems?

A: Exposure to the active substance is known to increase in patients with impaired kidney function. Official documents note that a dose adjustment may be considered by a healthcare provider for patients with impaired kidney function due to the potential for increased exposure to the active component.

---

Q: How does Vasonit retard affect blood pressure?

A: Studies have observed small decreases in blood pressure in some patients using this medicine. It is also noted that the medicine may lead to an additive blood pressure-lowering effect when used in combination with other drugs intended to lower blood pressure.

---

Q: What happens if I miss a dose of Vasonit retard?

A: The regulatory guidance provides specific protocols for handling a missed dose to help maintain a stable level of medicine in the bloodstream. The guidance describes timing requirements for when a missed dose should be taken or skipped, which is fully detailed in the Administration section.

---

Q: Does Vasonit retard interact with supplements like ginkgo biloba?

A: Official regulatory documents do not specifically name ginkgo biloba. However, they caution about a potential for increased bleeding risk when the medicine is used with any other agents that inhibit platelet aggregation, a property shared by certain herbal supplements.

---

Q: What kind of research has been done on Vasonit retard?

A: The primary research body consists of controlled trials that evaluated the medicine’s use in adult patients with conditions related to impaired microcirculation. This research has focused on the agent’s effects on blood flow properties, associated symptoms, and its safety profile over the duration of the studies.

---

Q: Is Vasonit retard safe for people with a history of heart issues?

A: Official documents note that the medicine has been used for peripheral arterial disease in patients who also have concurrent heart conditions. However, the side effect profile includes occasional reports of low blood pressure, chest pain (angina), and irregular heartbeat (arrhythmia).

---

Q: Does Vasonit retard affect sleep?

A: The official side effect lists include effects on the nervous system, such as dizziness and headache. Some studies involving certain patient groups have also reported insomnia (difficulty sleeping) as a mild side effect.

---

Q: Will Vasonit retard change my liver enzyme tests?

A: Regulatory information indicates that the medicine's exposure may be increased in patients with impaired liver function, which is why a dose adjustment may be considered. Furthermore, rare side effects noted in official documents include elevated liver enzymes and jaundice.

---

Q: Can I take Vasonit retard with indigestion medicine?

A: Official regulatory documents identify an interaction with Cimetidine, a drug used to reduce stomach acid, which can increase the concentration of the active substance in the body. Other general indigestion medicines are not specifically mentioned in the official interaction warnings.

---

Q: What are the signs of a serious interaction with Vasonit retard?

A: Official warnings about combining this medicine with others focus on effects such as increased bleeding risk and additive lowering of blood pressure. Official documents note that monitoring of the patient's blood system status or blood pressure is recommended when this medicine is used alongside other blood-system or blood pressure medicines.

---

Q: Is Vasonit retard appropriate for people who have had a stroke?

A: The medicine is strictly contraindicated (prohibited) for patients with a recent history of cerebral (brain) hemorrhage, which is a type of stroke. Caution is generally advised for all people with risk factors for bleeding.

---

Q: Can Vasonit retard affect vision or eyes?

A: Yes, official documentation lists certain effects on the eyes. The medicine is strictly contraindicated for individuals with extensive bleeding in the eye (retinal hemorrhage). Blurred vision is also noted as a possible adverse reaction.

---

Q: Does Vasonit retard have any warnings about driving or operating machinery?

A: Official product information advises that this medicine may cause drowsiness or dizziness. Individuals should recognize how the drug affects them before driving or operating machinery, as fully detailed in the Safety Precautions and Warnings section.

---

Q: Is Vasonit retard a type of vasodilator?

A: The medicine is primarily classified as a hemorheologic agent due to its effect on the flow properties of blood. Its mechanism, which improves microcirculation, involves modulating flow, and some scientific literature describes secondary effects potentially associated with widening blood vessels (vasodilation).

Storage Requirements

The medicine must be stored at room temperature, specifically between 68 F to 77 F (20 C to 25 C), with temperatures not exceeding 30 C. The official labeling requires that Vasonit retard be kept in its original container and protected from heat, moisture, and light. It is mandatory to keep the product from freezing.

Child Safety and Handling

For safety, the medication must be stored out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Vasonit retard must not be thrown away in household waste or flushed down the drain. Disposal must be handled according to local requirements, which typically involves returning the product to a pharmacist or using an approved medicine collection program to help protect the environment.